CATP: a 525-fold IL-12 result, and what it means for SV-Delivery™ buyers
A 2025 peer-reviewed paper from Yingzhong Li and colleagues shows a 525-fold intratumoral IL-12 amplification using SunVax LNPs to co-deliver self-amplifying mRNA. Here is what to make of the result if you are a buyer of SV-Delivery™ kits.
In August 2025, Yingzhong Li and six co-authors published a peer-reviewed paper in Communications Biology (PMID 40851032) describing a Cascade Amplification of Therapeutic Payloads — CATP — system. The headline number is striking: a 525-fold increase in intratumoral IL-12 in a B16F10 melanoma model. If you sell or buy SV-Delivery™ kits, this is the published version of what is happening behind the SV101/SV102/SV106 in vivo numbers you have seen at conferences.
The mechanism, in plain terms. CATP uses one lipid nanoparticle to deliver two RNA cargos at once: a self-amplifying mRNA (saRNA) plus a modified mRNA encoding alphavirus capsid and envelope proteins. The capsid + envelope build virus-like particles in situ, which then package and propagate the saRNA into neighboring cells. The saRNA amplifies itself once it gets there. The combination produces orders of magnitude more therapeutic payload than a single dose of conventional mRNA. Where a conventional mRNA-LNP dose would give you a 1× expression peak that decays over a few days, CATP gives you a peak that is itself a starting point.
What the 525× number does and does not say. It says: in mice, in melanoma, with IL-12 as the cargo, the team measured 525× more IL-12 in the tumor microenvironment than the unamplified comparator. It does NOT say this works in humans yet — the paper is preclinical, mouse-host. It does not say IL-12 is the right cargo for every solid tumor — it is the cargo for this particular paper. And it does not say CATP comes for free — the cost is delivering two different RNA species rather than one, which is more complex chemistry, more QA, and a larger LNP than a single-cargo kit.
Why this matters for a wet-lab buyer. If you are running a transient-expression experiment with mRNA, CATP is not what you order. SV101 or SV106 (single cargo, simpler protocol) is what you order. If you are exploring amplification of a therapeutic payload — IL-12 or otherwise — at the in vivo level, CATP is the published frame of reference. You will want to read the actual paper before designing the experiment, and you will want to talk to SunVax partnership rather than the kit catalog. The catalog is for transient expression; partnership is for the cascade.
Honest reading of the data. Communications Biology is a Nature-group journal with peer review. The data is real. The team — Li, Wu, Li, Wu, Wang, J. Li, Zhang — includes both SunVax staff and University of Michigan biomedical engineering collaborators. The path from this paper to a human clinical readout is still long: repeat-dosing immunogenicity (the unresolved question Yingzhong flagged on the 2026-05-15 panel), cross-species formulation, and regulatory framing all sit between today and the clinic. But "long path" is the right reading, not "skeptical." Buy SV-Delivery™ for what is on the order portal today; if you want what CATP points at, start the partnership conversation.
The right next click. If you want the kit catalog, you are one tab away at order.sunvaxmrna.com. If you want the cascade conversation, partners@sunvaxmrna.com or sunvaxmrna.com/partner is where to start. If you want to read the paper, the DOI in the sources below is open access on Nature.com.